INS and Hypoglycemia: Although the insulin dose was carefully titrated, patients experienced 0.21 ± 0.22 mild hypoglycemia and 0.02 ± 0.04 moderate hypoglycemia episodes per day during the 2~3 weeks of CSII therapy.